Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 3Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Neoplasms 1Glioblastoma 1Epilepsy 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Memantine × Clear all
NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting
120 enrolled
CNS

Epilepsy, Glioblastoma

NCT05834231 2023-04-28

Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity

Mansoura University

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡